Valtrex Peds (valacyclovir pediatric)

Valtrex Peds (valacyclovir pediatric) is filed as Antiviral. The sections below restate public label fields stored for this profile.

Class
Antiviral
Generic name
valacyclovir pediatric
Route
ORAL
Dosage forms
• Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS): Has occurred in patients with advanced HIV-1 disease and in allogenic bone marrow transplant and renal transplant patients receiving 8 grams per day of valacyclovir in clinical trials. Discontinue treatment if clinical symptoms and laboratory findings consistent with TTP/HUS occur. ( 5.1 ) • Acute renal failure: May occur in elderly patients (with or without reduced renal function), patients with underlying renal disease who receive higher- than-recommended doses of valacyclovir for their level of renal function, patients who receive concomitant nephrotoxic drugs, or inadequately hydrated patients. Use with caution in elderly patients and reduce dosage in patients with renal impairment. ( 2.4 , 5.2 ) • Central nervous system adverse reactions (e.g., agitation, hallucinations, confusion, and encephalopathy): May occur in both adult and pediatric patients (with or without reduced renal function) and in patients with underlying renal disease who receive higher-than-recommended doses of valacyclovir for their level of renal function. Elderly patients are more likely to have central nervous system adverse reactions. Use with caution in elderly patients and reduce dosage in patients with renal impairment. ( 2.4 , 5.3 ) • Severe cutaneous adverse reactions (SCARs): Including acute generalized exanthematous pustulosis (AGEP), drug reaction with eosinophilia and systemic symptoms (DRESS), toxic epidermal necrolysis (TEN), and Stevens-Johnson syndrome (SJS) have been reported during the postmarketing experience with valacyclovir. Discontinue valacyclovir immediately if a painful rash with mucosal involvement or a progressive severe rash develops, and closely monitor clinical status. (5.4)
Generic available
Yes
Manufacturer
NuCare Pharmaceuticals,Inc.

Approved uses

Valacyclovir tablet is a deoxynucleoside analogue DNA polymerase inhibitor indicated for: Adult Patients ( 1.1 ) • Cold Sores (Herpes Labialis) • Genital Herpes • Treatment in immunocompetent patients (initial or recurrent episode) • Suppression in immunocompetent or HIV-1-infected patients • Reduction of transmission • Herpes Zoster Pediatric Patients ( 1.2 ) • Cold Sores (Herpes Labialis) • Chickenpox Limitations of Use ( 1.3 ) The efficacy and safety of valacyclovir tablets have not been established in immunocompromised patients other than for the suppression of genital herpes in HIV-1-infected patients.

How it works

Valacyclovir is an antiviral drug active against α-herpes viruses [see Microbiology ( 12.4 )] .

Contraindications

Valacyclovir tabletsare contraindicated in patients who have had a demonstrated clinically significant hypersensitivity reaction [e.g., anaphylaxis, severe cutaneous adverse reactions (SCARs)] to valacyclovir, acyclovir, or any component of the formulation [see Warnings and Precautions (5.4) , Adverse Reactions (6.3) ].

Common side effects

Years were diarrhea (5%); Pyrexia (4%); Dehydration (2%); Herpes simplex (2%); And rhinorrhea (2%)

Adverse reactions

The following serious adverse reactions are discussed in greater detail in other sections of the labeling: • Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome [see Warnings and Precautions ( 5.1 )]. • Acute Renal Failure [see Warnings and Precautions ( 5.2 )]. • Central Nervous System Effects [see Warnings and Precautions ( 5.3 )]. • Severe Cutaneous Adverse Reactions [see Warnings and Precautions ( 5.4 )]. The most common adverse reactions reported in at least 1 indication by greater than 10% of adult subjects treated with valacyclovir and observed more frequently with valacyclovir compared with placebo are headache, nausea, and abdominal pain. The only adverse reaction reported in greater than 10% of pediatric subjects aged less than 18 years was headache.

Dosage and administration

Valacyclovir tablets may be given without regard to meals. • Valacyclovir oral suspension (25 mg/mL or 50 mg/mL) may be prepared extemporaneously from 500-mg valacyclovir tablets for use in pediatric patients for whom a solid dosage form is not appropriate [see Dosage and Administration ( 2.3 )].

Drug interactions

No clinically significant drug-drug or drug-food interactions with valacyclovir are known [see Clinical Pharmacology ( 12.3 )].

Common questions

What is Valtrex Peds approved to treat?

According to its FDA label, Valtrex Peds (valacyclovir pediatric) is approved for: Valacyclovir tablet is a deoxynucleoside analogue DNA polymerase inhibitor indicated for: Adult Patients ( 1.1 ) • Cold Sores (Herpes Labialis) • Genital Herpes • Treatment in immunocompetent patients (initial or recurrent episode) • Suppression in immunocompetent or HIV-1-infect… For medical advice, please talk to your prescriber or pharmacist.

What class of drug is Valtrex Peds?

Valtrex Peds (valacyclovir pediatric) belongs to the Antiviral class of medications.

What form does Valtrex Peds come in?

The FDA label lists Valtrex Peds (valacyclovir pediatric) as: Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS): Has occurred in patients with advanced HIV-1 disease and in allogenic bone marrow transplant and renal transplant patients receiving 8 grams per day of valacyclovir in clinical trials. Discontinue treatment if clinical symptoms and laboratory findings consistent with TTP/HUS occur. ( 5.1 ) • Acute renal failure: May occur in elderly patients (with or without reduced renal function), patients with underlying renal disease who receive higher- than-recommended doses of valacyclovir for their level of renal function, patients who receive concomitant nephrotoxic drugs, or inadequately hydrated patients. Use with caution in elderly patients and reduce dosage in patients with renal impairment. ( 2.4 , 5.2 ) • Central nervous system adverse reactions (e.g., agitation, hallucinations, confusion, and encephalopathy): May occur in both adult and pediatric patients (with or without reduced renal function) and in patients with underlying renal disease who receive higher-than-recommended doses of valacyclovir for their level of renal function. Elderly patients are more likely to have central nervous system adverse reactions. Use with caution in elderly patients and reduce dosage in patients with renal impairment. ( 2.4 , 5.3 ) • Severe cutaneous adverse reactions (SCARs): Including acute generalized exanthematous pustulosis (AGEP), drug reaction with eosinophilia and systemic symptoms (DRESS), toxic epidermal necrolysis (TEN), and Stevens-Johnson syndrome (SJS) have been reported during the postmarketing experience with valacyclovir. Discontinue valacyclovir immediately if a painful rash with mucosal involvement or a progressive severe rash develops, and closely monitor clinical status. (5.4); oral route. Available strengths and packaging vary by manufacturer.

Is there a generic version of Valtrex Peds?

Yes. A generic version of Valtrex Peds (valacyclovir pediatric) is available in the U.S. Ask your pharmacist about substitution.

Does Valtrex Peds have a Boxed Warning?

Our ingest of the FDA label for Valtrex Peds (valacyclovir pediatric) does not include a Boxed Warning at this time. See the full label on DailyMed for the current, authoritative version.

How much does Valtrex Peds cost?

Public CMS NADAC pricing for Valtrex Peds (valacyclovir pediatric) is in the range Retail prices vary widely by pharmacy, insurance, and location. Check with your pharmacy or use tools like GoodRx for current pricing.. Retail price varies by pharmacy, insurance, and manufacturer coupons.

Is Valtrex Peds currently under recall?

The FDA Enforcement Report does not show an active/ongoing recall for Valtrex Peds (valacyclovir pediatric) in our latest ingest. Recall data can change daily — verify at FDA.gov.

When was Valtrex Peds approved by the FDA?

The FDA record lists the approval date for Valtrex Peds (valacyclovir pediatric) as 2020-03-18.

Who makes Valtrex Peds?

The FDA label lists NuCare Pharmaceuticals,Inc. as a labeler/manufacturer of Valtrex Peds (valacyclovir pediatric). Multiple firms may market generics of the same molecule.

How should Valtrex Peds be stored?

The FDA label states: "Valacyclovir Tablets USP, 1 gm are white to off-white, film-coated, capsule shaped tablets, debossed with 'I' on one side and '87' on other side with partial scorebar on both sides. They are supplied in NDC: 70518-2402-0…" Follow the packaging insert for the authoritative guidance.

On this site

Related medications in this class or category

Loading full data from Know Your Drugs Institute…